Are you Dr. El-Osta?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 41 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
6400 Fannin St
Suite 2900
Houston, TX 77030Phone+1 832-325-7702Fax+1 713-512-7132- Is this information wrong?
Summary
- Dr. Hazem El-Osta, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas and Louisiana. He is an Assistant Professor at LA State Univ Sch of Med.
Education & Training
Louisiana State University School of MedicineFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Kansas (Wichita)Residency, Internal Medicine, 2006 - 2009
St Joseph's University Medical SchoolClass of 2004
Certifications & Licensure
TX State Medical License 2016 - 2025
LA State Medical License 2010 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Publications & Presentations
PubMed
- 7 citationsBrief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Wei Tu, Courtney H Coschi, Federica Grosso, Marie Florescu, Manlio Mencoboni, John R Goffin, Maria Pagano, For...> ;Journal of Thoracic Oncology. 2023 Jun 1
- 7 citationsReal-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data.Vamsidhar Velcheti, Xiaohan Hu, Yeran Li, Hazem El-Osta, M Catherine Pietanza, Thomas Burke> ;Cancers. 2022 Feb 18
- 11 citationsPredictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysisHazem E El-Osta, Frank E. Mott, Bryan M. Burt, Daniel Y. Wang, Anita L. Sabichi> ;Oncoimmunology. 2019 Sep 20
- Join now to see all
Other Languages
- French, Arabic
